Tempest Therapeutics (NASDAQ:TPST) Raised to Hold at Wall Street Zen

Tempest Therapeutics (NASDAQ:TPST) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Saturday, Wall Street Zen reports.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Tempest Therapeutics in a research report on Friday, October 9th. One research analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Reduce”.

Tempest Therapeutics Stock Performance

Shares of Tempest Therapeutics stock opened at $0.51 on Friday. The stock has a 50 day moving average of $0.87 and a 200 day moving average of $1.22. Tempest Therapeutics has a 12 month low of $0.50 and a 12 month high of $11.13. The firm has a market cap of $8.63 million, a PE ratio of -0.12 and a beta of -1.73.

Tempest Therapeutics (NASDAQ:TPST) last released its quarterly earnings results on Thursday, August 13th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.30) by ($0.04). As a group, equities research analysts forecast that Tempest Therapeutics will post -0.83 earnings per share for the current fiscal year.

Institutional Trading of Tempest Therapeutics

An institutional investor recently bought a new stake in Tempest Therapeutics stock. Squarepoint Ops LLC acquired a new stake in shares of Tempest Therapeutics, Inc. (NASDAQ:TPST) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 30,900 shares of the company’s stock, valued at approximately $34,000. Squarepoint Ops LLC owned 0.19% of Tempest Therapeutics at the end of the most recent reporting period. 22.52% of the stock is currently owned by institutional investors and hedge funds.

Tempest Therapeutics Company Profile

Tempest Therapeutics, Inc is a clinical-stage biotechnology company focused on developing small-molecule medicines for cancer. The company’s research combines tumor-targeted immune activation with approaches designed to disrupt tumor metabolism, with the goal of stimulating the immune system within the tumor microenvironment while limiting effects on healthy tissue.

Tempest’s pipeline has included TPST-1120, an oral, selective antagonist of peroxisome proliferator-activated receptor alpha (PPARα).